Sugi Predict

Sugi Predict / Compounds / SCHEMBL701658

SCHEMBL701658

SCHEMBL701658

C[C@@H](N)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.67
▸ ADRB2 P07550 1/20 0.50
▸ KIF11 P52732 2/20 0.43
▸ CES2 O00748 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ HTR2A P28223 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ CASR P41180 2/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.40
▸ ACP3 P15309 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335039 1.00 PDE2A (0.67) PDE2AADRB2KIF11CES2CES1
SCHEMBL268077 1.00 PDE2A (0.67) PDE2AADRB2KIF11CES2CES1
Bromide SCHEMBL28801001 0.98 PDE2A (0.64) PDE2AADRB2KIF11CES2CES1
Hydrochloric Acid SCHEMBL4935636 0.98 PDE2A (0.64) PDE2AADRB2KIF11CES2CES1
Hydrochloric Acid SCHEMBL20266800 0.98 PDE2A (0.64) PDE2AADRB2KIF11CES2CES1
Iodide SCHEMBL28800992 0.98 PDE2A (0.64) PDE2AADRB2KIF11CES2CES1
Hydrochloric Acid SCHEMBL27940422 0.98 PDE2A (0.64) PDE2AADRB2KIF11CES2CES1
SCHEMBL30913861 0.94 PDE2A (0.60) PDE2AADRB2KIF11CASR
SCHEMBL13448214 0.88 PDE2A (0.55) PDE2AADRB2
SCHEMBL30828328 0.86 PDE2A (0.52) PDE2AADRB2KIF11CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109851506-B Asymmetric reductive amination of simple ketones catalyzed by ruthenium-bisphosphine catalysts to prepare chiral primary amines 凯特立斯（深圳）科技有限公司 2020-09-15 — — CN claimed
US-9133187-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-09-15 — — US claimed
EP-2681215-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-22 — — EP claimed
EP-2121617-B1 CB1 RECEPTOR MODULATORS 7TM PHARMA AS (DK) 2014-01-22 — — EP claimed
US-20100010061-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2010-01-14 — — US claimed
EP-2121617-A1 CB1 RECEPTOR MODULATORS 7TM Pharma A/S (DK) 2009-11-25 — — EP claimed
EP-2094666-A1 CANNABINOID RECEPTOR MODULATORS 7TM Pharma A/S (DK) 2009-09-02 — — EP claimed
WO-2008075012-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2008-06-26 — — WO claimed
WO-2008059207-A1 CANNABINOID RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2008-05-22 — — WO claimed
US-7081551-B2 Optically active (R)-1-(4-trifluoromethylphenyl)ethylamine CENTRAL GLASS CO., LTD. (JP) 2006-07-25 — — US claimed
US-20040024253-A1 Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-05 — — US claimed
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-29 — — US disclosed
EP-4567038-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-06-11 — — EP disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 — — CN disclosed
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2004-11-25 — — US disclosed
US-20040024253-A1 Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-05 — — US disclosed
US-20040024253-A1 Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-05 — — US disclosed
US-20040024253-A1 Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-05 — — US disclosed
JP-2003335737-A OPTICALLY ACTIVE (R)-1-(4-TRIFLUOROMETHYLPHENYL) ETHYLAMINE CENTRAL GLASS CO LTD 2003-11-28 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same NAT1, PNMT, AFF1 PDE2A 1807/4885ADRB2 37/4885KIF11 2616/4885
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives GPR139, GPR119, GPR39 PDE2A 414/4885ADRB2 58/4885KIF11 1995/4885
US-20040024253-A1 Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine HPD, ALDH1A2, DHPS PDE2A 4147/4885ADRB2 864/4885KIF11 4032/4885
US-20100010061-A1 CB1 RECEPTOR MODULATORS CNR1, CNR2, GPR6 PDE2A 3469/4885ADRB2 171/4885KIF11 3251/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 PDE2A 2539/4885ADRB2 912/4885KIF11 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.